Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Physiomics ( (GB:PYC) ).
Physiomics plc has launched a Winterflood Retail Access Platform offer to raise up to £49,999.98 by issuing up to 16,666,660 new ordinary shares at £0.003 each, matching the price of a concurrent institutional placing of approximately £499,999.86. The fundraising, which is subject to shareholder approval at a 7 April 2026 general meeting and admission of the new shares to AIM around 8 April, is structured to give existing UK retail shareholders the chance to participate on the same terms as placing investors, potentially broadening the shareholder base while diluting existing holdings.
The WRAP Retail Offer is open only to existing UK shareholders via participating intermediaries, with a minimum subscription of £100 and the company retaining discretion over scaling back or rejecting applications. New shares issued under the offer will rank pari passu with existing stock, and the structure utilises UK prospectus exemptions, indicating a relatively small but strategically inclusive capital raise intended to support the same objectives as the larger placing without the cost and delay of a full prospectus.
The most recent analyst rating on (GB:PYC) stock is a Hold with a £0.44 price target. To see the full list of analyst forecasts on Physiomics stock, see the GB:PYC Stock Forecast page.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Neutral.
The score is held back primarily by weak financial performance—persistent losses and ongoing cash burn despite a debt-free balance sheet and a 2025 revenue rebound. Technicals are supportive with price above major moving averages, but overbought signals raise near-term risk. Valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is an AIM‑quoted mathematical modelling, data science and biostatistics specialist focused on supporting biotech and pharma companies in developing new therapeutics and personalised medicine solutions. Leveraging proprietary tools such as its Virtual Tumour technology, the company integrates modelling, bioinformatics and biology expertise to de‑risk decision‑making and optimise discovery, pre‑clinical and clinical study design.
Average Trading Volume: 6,261,963
Technical Sentiment Signal: Sell
Current Market Cap: £1.36M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.